Ferrous Asparto Glycinate
Active ingredient
Sold as Chromagen
- Drug class
- -
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
- FDA reports (12 mo)
- 8
Overview
Plain-language summary, compiled from the cited regulatory records
Ferrous Asparto Glycinate is an active ingredient used in dietary supplements [1]. It is indicated for improving the nutritional status of patients experiencing iron deficiency [1]. This ingredient is available in the market under various brand names, including Chromagen [1].
In the past 12 months, there have been 8 adverse event reports associated with products containing Ferrous Asparto Glycinate [2]. The most frequently reported adverse events include Acute Kidney Injury, Compression Fracture, Drug Interaction, Intestinal Angioedema, and Overdose [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | April 8, 2026 |
USUnited States· FDA
1 product
Uses
INDICATIONS:
Chromagen™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.
How to take
Sources & citations
- [1]FDA DailyMed · 13c5ed58-6333-49… · revised April 8, 2026 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.